Homology Modeling and Evaluation of Sars-Cov-2 Spike Protein Mutant: D614G

View Sample PDF

Author(s): Hima Vyshnavi (Accubits Invent Pvt. Ltd., India), Aswin Mohan (Accubits Invent Pvt. Ltd., India), Shahanas Naisam (Accubits Invent Pvt. Ltd., India), Suvanish Kumar (Accubits Invent Pvt. Ltd., India)and Nidhin Sreekumar (Accubits Invent Pvt. Ltd., India)
Copyright: 2024
Pages: 20
Source title: Research Anthology on Bioinformatics, Genomics, and Computational Biology
Source Author(s)/Editor(s): Information Resources Management Association (USA)
DOI: 10.4018/979-8-3693-3026-5.ch039

Keywords: Bioinformatics / Medical Information Science Reference / Medicine & Healthcare

Purchase

View Homology Modeling and Evaluation of Sars-Cov-2 Spike Protein Mutant: D614G on the publisher's website for pricing and purchasing information.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS‐Cov-2), a global pandemic, affected the world, increasing every day. A mutated variant D614G, showing more virulence and transmission, was studied for forecasting the emergence of more virulent and pathogenic viral strains. This study focuses on structure modeling and validation. Characterization of proteins homologous to wild spike protein was done, and homology models of the mutated variant were modeled using these proteins. Validation of models was done using Ramachandran plot and ERRAT plot. Molecular dynamics simulation was used to validate the stability of the models, and binding affinity of these models were estimated by molecular docking with an approved antiviral drug. Docked complexes were studied and the best model was selected. Molecular dynamics simulation was used to estimate the stability of the docked complex. The model of 6VXX, a homologous of wild spike protein, was found to be stable with the interaction of the antiviral drug from this study.

The IRMA Community

Research IRM

Homology Modeling and Evaluation of Sars-Cov-2 Spike Protein Mutant: D614G

Purchase

Abstract

Related Content

IRMA Sponsors